Newer prostate Ca agent shows positive pain outcomes

Article

Recent studies of the oral androgen receptor inhibitor enzalutamide (Xtandi) evaluated the effect of costicosteroid use with the agent as well as its pain-related outcomes in patients with advanced prostate cancer.

Recent Videos
Elisabeth M. Sebesta, MD, answers a question during a Zoom video interview
Kyrollis Attalla, MD, an expert on prostate cancer
Kyrollis Attalla, MD, an expert on prostate cancer
Marc Bjurlin, DO, MSc, FACOS, answers a question during a Zoom video interview
Jacqueline Zillioux, MD, answers a question during a Zoom video interview
DNA molecules | Image Credit: © vitstudio - stock.adobe.com
Related Content
© 2024 MJH Life Sciences

All rights reserved.